Congress extends pharma pricing shield, delaying Medicare drug negotiations
H.R. 1492 — To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. · Filed by Gregory Murphy (R-NC) · 68 cosponsors · Introduced Feb 21, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill extends the period during which biologic drugs are protected from Medicare price negotiation from 7 years to 11 years, matching the protection period for small-molecule drugs. Biologic manufacturers gain a longer window before their prices can be negotiated by Medicare, while Medicare and taxpayers face higher drug costs for a longer period.
Why we flagged it
The bill's sole operative effect is to extend the period during which biologic drug manufacturers are shielded from Medicare price negotiation. This is a direct extension of market protection for a specific industry segment.
What the text implies
- The 11-year period now matches small-molecule drugs, but biologics typically have higher per-unit costs and longer market lifecycles, so the extended protection may have outsized fiscal impact on Medicare spending.
- The retroactive effective date ('as if included in the enactment of Public Law 117–169') may affect the calculation of exclusion periods for biologics already in the market, potentially extending protections for drugs already approved.
The full analysis lists 3 implications of this text.
Who stands to gain
biologic pharmaceutical manufacturers; large-cap pharma companies with biologic portfolios